Tykerb patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8821927 NOVARTIS Pharmaceutical composition
Sep, 2029

(5 years from now)

Tykerb is owned by Novartis.

Tykerb contains Lapatinib Ditosylate.

Tykerb has a total of 1 drug patent out of which 0 drug patents have expired.

Tykerb was authorised for market use on 13 March, 2007.

Tykerb is available in tablet;oral dosage forms.

The generics of Tykerb are possible to be released after 18 September, 2029.

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

Market Authorisation Date: 13 March, 2007

Treatment: NA


How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage

TYKERB family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic